Literature DB >> 26437785

Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.

J-P Defour1, I Chachoua1, C Pecquet1, S N Constantinescu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26437785     DOI： 10.1038/leu.2015.271

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Pathogenesis of myeloproliferative neoplasms.

Authors:  Radek C Skoda; Adrian Duek; Jean Grisouard
Journal:  Exp Hematol       Date:  2015-07-21       Impact factor: 3.084

2.  A model for sulfhydryl groups in proteins. Hydrophobic interactions of the cystein side chain in micelles.

Authors:  P Heitmann
Journal:  Eur J Biochem       Date:  1968-01

3.  Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.

Authors:  Christian Pecquet; Judith Staerk; Ronan Chaligné; Valerie Goss; Kimberly A Lee; Xiaowu Zhang; John Rush; Joanne Van Hees; Hélène A Poirel; Jean-Marie Scheiff; William Vainchenker; Stéphane Giraudier; Roberto D Polakiewicz; Stefan N Constantinescu
Journal:  Blood       Date:  2009-12-08       Impact factor: 22.113

4.  The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.

Authors:  Veena Sangkhae; S Leah Etheridge; Kenneth Kaushansky; Ian S Hitchcock
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

5.  An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.

Authors:  Judith Staerk; Catherine Lacout; Takeshi Sato; Steven O Smith; William Vainchenker; Stefan N Constantinescu
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

6.  MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.

Authors:  Wanlong Ma; Xi Zhang; Xiuqiang Wang; Zhong Zhang; Chen-Hsiung Yeh; Jennifer Uyeji; Maher Albitar
Journal:  Diagn Mol Pathol       Date:  2011-03

7.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Authors:  Animesh D Pardanani; Ross L Levine; Terra Lasho; Yana Pikman; Ruben A Mesa; Martha Wadleigh; David P Steensma; Michelle A Elliott; Alexandra P Wolanskyj; William J Hogan; Rebecca F McClure; Mark R Litzow; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

8.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

9.  CYSTM, a novel cysteine-rich transmembrane module with a role in stress tolerance across eukaryotes.

Authors:  Thiago M Venancio; L Aravind
Journal:  Bioinformatics       Date:  2009-11-17       Impact factor: 6.937

10.  MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

Authors:  Philip A Beer; Peter J Campbell; Linda M Scott; Anthony J Bench; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Hans C Hasselbalch; Richard Bowman; Keith Wheatley; Georgina Buck; Claire N Harrison; Anthony R Green
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113
View more
  15 in total

1.  An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis.

Authors:  J-P Defour; Y Hoade; A-M Reuther; A Callaway; D Ward; F Chen; S N Constantinescu; N C P Cross
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

2.  Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model.

Authors:  Brahim Arkoun; Elie Robert; Fabien Boudia; Stefania Mazzi; Virginie Dufour; Aurélie Siret; Yasmine Mammasse; Zakia Aid; Matthieu Vieira; Imanci Aygun; Marine Aglave; Marie Cambot; Rachel Petermann; Sylvie Souquere; Philippe Rameau; Cyril Catelain; Romain Diot; Gérard Tachdjian; Olivier Hermine; Nathalie Droin; Najet Debili; Isabelle Plo; Sébastien Malinge; Eric Soler; Hana Raslova; Thomas Mercher; William Vainchenker
Journal:  J Clin Invest       Date:  2022-07-15       Impact factor: 19.456

3.  A network map of thrombopoietin signaling.

Authors:  Firdous A Bhat; Jayshree Advani; Aafaque Ahmad Khan; Sonali Mohan; Arnab Pal; Harsha Gowda; Prantar Chakrabarti; T S Keshava Prasad; Aditi Chatterjee
Journal:  J Cell Commun Signal       Date:  2018-07-24       Impact factor: 5.782

Review 4.  Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.

Authors:  Isabelle Plo; Christine Bellanné-Chantelot; Matthieu Mosca; Stefania Mazzi; Caroline Marty; William Vainchenker
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-12       Impact factor: 5.555

Review 5.  The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin.

Authors:  Leila N Varghese; Jean-Philippe Defour; Christian Pecquet; Stefan N Constantinescu
Journal:  Front Endocrinol (Lausanne)       Date:  2017-03-31       Impact factor: 5.555

Review 6.  MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment.

Authors:  Julian Grabek; Jasmin Straube; Megan Bywater; Steven W Lane
Journal:  Cells       Date:  2020-08-14       Impact factor: 6.600

7.  Somatic mutations and cell identity linked by Genotyping of Transcriptomes.

Authors:  Anna S Nam; Kyu-Tae Kim; Ronan Chaligne; Franco Izzo; Chelston Ang; Justin Taylor; Robert M Myers; Ghaith Abu-Zeinah; Ryan Brand; Nathaniel D Omans; Alicia Alonso; Caroline Sheridan; Marisa Mariani; Xiaoguang Dai; Eoghan Harrington; Alessandro Pastore; Juan R Cubillos-Ruiz; Wayne Tam; Ronald Hoffman; Raul Rabadan; Joseph M Scandura; Omar Abdel-Wahab; Peter Smibert; Dan A Landau
Journal:  Nature       Date:  2019-07-03       Impact factor: 49.962

8.  Two activating mutations of MPL in triple-negative myeloproliferative neoplasms.

Authors:  Juan Xie; Xiuhua Chen; Feng Gao; Ruixia Hou; Tingting Tian; Yaofang Zhang; Lifang Fan; Jinjun Hu; Guiyang Zhu; Wanfang Yang; Hongwei Wang
Journal:  Cancer Med       Date:  2019-07-11       Impact factor: 4.452

Review 9.  Molecular pathogenesis of the myeloproliferative neoplasms.

Authors:  Graeme Greenfield; Mary Frances McMullin; Ken Mills
Journal:  J Hematol Oncol       Date:  2021-06-30       Impact factor: 17.388

Review 10.  Recent advances in understanding myelofibrosis and essential thrombocythemia.

Authors:  William Vainchenker; Stefan N Constantinescu; Isabelle Plo
Journal:  F1000Res       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.